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Abstract
Pompe disease is an autosomal recessive lysosomal storage disorder caused by
disease‐associated variants in the acid alpha‐glucosidase (GAA) gene. The current
Pompe mutation database provides a severity rating of GAA variants based on in silico
predictions and expression studies. Here, we extended the database with clinical
information of reported phenotypes. We added additional in silico predictions for
effects on splicing and protein function and for cross reactive immunologic material
(CRIM) status, minor allele frequencies, and molecular analyses. We analyzed 867
patients and 562 GAA variants. Based on their combination with a GAA null allele (i.e.,
complete deficiency of GAA enzyme activity), 49% of the 422 disease‐associated
variants could be linked to classic infantile, childhood, or adult phenotypes.
Predictions and immunoblot analyses identified 131 CRIM negative and 216 CRIM
positive variants. While disease‐associated missense variants were found throughout
the GAA protein, they were enriched up to seven‐fold in the catalytic site. Fifteen
percent of disease‐associated missense variants were predicted to affect splicing. This
should be confirmed using splicing assays. Inclusion of clinical severity rating in the
Pompe mutation database provides an invaluable tool for diagnosis, prognosis of
disease progression, treatment regimens, and the future development of personalized
medicine for Pompe disease.
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1 | INTRODUCTION
Pompe disease or glycogen storage type II (MIM# 232300) is
an autosomal recessive disorder caused by deficiency of acid
α‐glucosidase (GAA; NP_000143.2). Partial or complete GAA
deficiency is caused by disease‐associated sequence variants in the
GAA gene, resulting in lysosomal glycogen accumulation in many cell
types, with profound pathology in cardiac and skeletal muscle.
Pompe disease presents as a spectrum of phenotypes. Classic
infantile patients have a rapidly progressing phenotype, with
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hypertrophic cardiomyopathy and general muscle weakness. Without
therapy, these patients die within the first year of life. Patients with
symptom onset at childhood or adulthood have a more slowly
progressive disease, leading to mobility problems and respiratory
difficulties, but generally without hypertrophic cardiomyopathy.
Most of these patients will become ventilator and wheelchair
dependent at some point in time (Gungor & Reuser, 2013; Reuser,
Hirschhorn, & Kroos, 2018; Schoser et al., 2015).
The standard treatment for Pompe disease is enzyme replace-
ment therapy (ERT) with recombinant human GAA (rhGAA). In classic
infantile Pompe disease, ERT reduces cardiac hypertrophy, improves
survival, and helps to achieve important developmental milestones
that were previously unmet (Chakrapani, Vellodi, Robinson, Jones, &
Wraith, 2010; Kishnani et al., 2009; Van den Hout et al., 2000).
Numerous studies in children and adults have shown improvement of
muscle strength, stabilization of pulmonary function, decreased
fatigue, and extended survival. However, there is variation in
response and not all patients respond equally well (Broomfield
et al., 2016; de Vries et al., 2012; Gungor et al., 2013; Gungor et al.,
2016; Hahn et al., 2018; Kuperus et al., 2017; Papadopoulos et al.,
2017; Regnery et al., 2012; Stepien, Whitby, Roberts, & Sharma,
2015; Strothotte et al., 2010; van Capelle et al., 2010; van der Ploeg
et al., 2010).
Patients who do not produce detectable GAA protein are termed
cross reactive immunologic material (CRIM) negative. In these
patients, both alleles carry a CRIM negative variant, and the
phenotype is per definition classic infantile. Whereas CRIM positive
patients have at least one disease‐associated GAA variant that allows
expression of GAA protein, the protein produced is enzymatically
inactive due to misfolding, defects in glycosylation, defects in
intracellular routing to the lysosome, and so forth. The second allele
in CRIM positive patients can contain either a CRIM positive or a
CRIM negative GAA variant. CRIM positive patients who have no
detectable GAA enzyme activity develop a classic infantile pheno-
type, whereas patients with a childhood or adult phenotype still
retain some enzymatic activity and are therefore always CRIM
positive. CRIM negative infants have a greater tendency to develop
anti‐GAA neutralizing antibodies compared to CRIM positive infants
(Kishnani et al., 2010; van Gelder et al., 2016). Therefore, it is
important to establish the CRIM status of GAA variants.
The rapidly expanding number of GAA sequence variants that
have been discovered over the past 15 years has provided the basis
for the establishment of the Pompe disease mutation database
at www.pompevariantdatabase.nl. The present version of the Pompe
mutation database lists all known GAA variants and provides a
prediction of pathogenicity based on results obtained by in silico
prediction algorithms, from the measured effect on GAA synthesis
and enzymatic function when expressed in vitro, and from the type of
variant. This approach resulted in a rating system with six different
categories ranging from “very severe” to “nonpathogenic” (M. Kroos
et al., 2008; M. A. Kroos et al., 2012). Here, we have extended the in
silico predictions by analyzing all GAA variants using Alamut software
for effects on RNA processing and protein function, and used these in
silico predictions as well as published data to report or predict CRIM
status. We scrutinized the literature and report clinical phenotypes
that are associated with GAA variants.
The results of our study described here have been included in the
update of the Pompe mutation database, that will from now on be
referred to as the “Pompe disease GAA variant database” under the
link (www.pompevariantdatabase.nl). The improved database should
help doctors, genetic counselors and scientists to better predict
disease outcome in patients diagnosed with Pompe disease. As well
as providing new insight into variant severity, it will also improve
prediction of prognosis in newborn screening programs, and support
decision‐making on therapeutic intervention.
2 | METHODS
2.1 | Annotation of variants
Variant annotations and classification conform to recommendations
of the human genome variation society (HGVS) according to update
2016 (den Dunnen et al., 2016). NM_000152.3 was used as reference
sequence for GAA mRNA. Annotation of variants present in intronic
regions were based on the LRG_673 reference sequence. Position c.1
represents the first nucleotide of the translation start codon ATG
located in exon 2. NP_000143.2 was used for annotation of GAA
protein variants.
2.2 | Minor allele frequency and reference SNP
number
Minor allele frequency (MAF) was examined using dbSNP, Exac,
Genome of the Netherlands (GoNL), ESP, and HGVD, with 1 January
2017 as last entry. The MAF reported in the database was based on
the highest MAF score seen in any of the aforementioned databases.
The link for the most recent information on MAF has been provided
in the database. Reference SNP (RS) numbers, when available, are
also provided.
2.3 | In silico prediction of pathogenicity
These were performed using Alamut software. Missense predictions
were performed using Mutation Taster, SIFT, and Align GVGD.
2.4 | Splicing prediction
Splice variants were defined as intronic positions −1 and −2 relative
to the canonical splice acceptor site, and intronic positions +1 and +2
relative to the canonical splice donor site. So far, all splice variants
defined in this way had been listed as “very severe”. To better
evaluate variants’ possible effect on pre‐mRNA splicing, we re‐
evaluated all variants using Alamut® software and provided this
information in the database (Algorithms used are listed in Table S1).
Splice predictions were deemed to potentially affect splicing when at
least two of the five algorithms predicted more than a 10% difference
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in splice site strength as described previously (Bergsma et al., 2015).
In some cases it was possible to use the literature to retrieve
functional evidence of variants that affect splicing. These findings
were added to the column “biochemical evidence of pathogenicity”.
2.5 | Prediction of CRIM status
If CRIM status had been determined experimentally by endogenous
protein (i.e., immunoblot) or RNA expression (i.e., RT‐qPCR) analysis,
this was indicated at the “variant info” page under “biochemical
evidence of CRIM status” or “biochemical evidence of pathogenicity”,
respectively. We also predicted CRIM status based on the type of
variant for all variants, and reported this in the database. Variants
that caused a frame shift were predicted to be CRIM negative.
Missense variants were predicted to be CRIM positive, provided that
no effect on splicing was predicted. Known and predicted splice
variants were classified with an “unknown” CRIM status, unless
experimental evidence was reported on expression of in‐frame
mRNA transcripts. Please note that a) all prediction need to be
confirmed experimentally. For example, it is known that certain
variants that cause a premature stop codon can escape nonsense‐
mediated decay. In those cases, the actual CRIM status could be
positive rather than negative. It is also known that splicing outcome
is difficult to predict (e.g., see Bergsma et al., 2015). b) the CRIM
status of a patient is determined by two disease‐associated variants,
and all patients with symptom onset at childhood or adulthood have
some residual GAA enzyme activity. For this reason, these patients
always have a CRIM positive status, caused by the presence of at
least one CRIM positive variant.
2.6 | Patient classification and phenotypic
information
We classified published patient information based on the criteria
stated in Gungor and Reuser (2013). Patients were classified with
classic infantile Pompe disease if they presented symptoms at or
under 12 months of age, and had evident signs of a hypertrophic
cardiomyopathy (cardiac enlargement visible on chest X‐ray,
evidence of hypertrophy by echography). Patients were classified
with childhood Pompe disease if the age of symptom onset was
before 18 years of age and evident hypertrophic cardiomyopathy
was absent. Patients were classified with adult Pompe disease if
the first symptoms presented at the age of 18 years or later. If
specific clinical information was reported in the literature, it was
included in the database as indicated. Since familial connections
were not always clearly stated in publications, no familial
connections were taken into account and all cases were reported
independently. We did all we could to avoid duplicating patients
who had been described in more than one publication. It
nonetheless remains possible that some duplicate cases were not
detected.
2.7 | Availability of the data
The open access Pompe disease GAA variant database is available
at www.pompevariantdatabase.nl.
In addition, all variants and patient phenotypes associated with
the variants are included in the Leiden Open Variation Database
(LOVD) at www.LOVD.nl/GAA.
3 | RESULTS
3.1 | Overview of the updated Pompe database
A flow chart for the criteria used for clinical severity rating is given in
Figure 1a. Clinical severity rating of variants was performed based on
patients with two identified GAA variants, at least one of which was a
null allele, which is defined as a GAA variant who's protein product lacks
any detectable GAA enzyme activity. The classification of null alleles
(listed in Table S2) was made based on their association with the classic
infantile phenotype. In some cases data have been reported that are
derived from site directed mutagenesis of GAA expression constructs,
but no patients have been reported that have such variant. In those
cases, the clinical phenotype was classified as “unknown”. When
patients were reported but the second GAA allele was not a null allele,
was not reported or had an unknown severity, the clinical phenotype
was classified as unknown (disease‐associated). In those cases, the
variant does cause Pompe disease because patients have been reported,
and thus this variant is disease‐associated. However the variant cannot
be associated to a certain phenotype because the contribution of the
second allele to the phenotype is unknown.
The updated open access Pompe disease GAA variant database is
available at www.pompevariantdatabase.nl. The main access page
contains the most essential information, including a) the location of
the variant based on exon or intron number, b) the DNA, RNA and
protein nomenclature according to the recommendations of the
HGVS (version 2016) (den Dunnen et al., 2016), c) the predicted
severity, d) the phenotype when combined with a null alelle, e) the
CRIM status according to literature reports or based on prediction
according to type of variant, and f) links to the variants and to the
patients described in the literature. (Figure 1b).
The link to variants includes the type of variants, their predicted
severity, the phenotype of variants when combined with a null allele,
biochemical evidence and in silico prediction of (non‐) pathogenicity,
MAF, RS‐number, biochemical evidence and in silico prediction of
CRIM status, splicing prediction for all variants using different
prediction algorithms, severity predictions for all missense variants,
and the link to publications on the variant. The link to patients
contains the clinical phenotype of patients found in the literature
with that variant in combination with a second disease‐associated
variant, additional clinical symptoms, the patients’ geographical
location, and the link to publications in which the patient was
reported. The extended database includes an analysis of all data
contained in the Pompe disease mutation database. Eight new
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variants have been added since the last update in May 2016
(Table S3).
3.2 | Analysis of GAA variants based on clinical
phenotype
Of the total number of 562 described variants, 422 are listed as
disease‐associated. We analyzed types of GAA variants according to
their RNA and protein nomenclature (HGVS version 2016), and
stratified these based on the clinical phenotype, being classic
infantile, childhood, or adult (Figure 2). The variants present in a
total of 867 patients were analyzed (Figure S2). In 49% of patients
with Pompe disease reported in the mutation database (data not
shown), the second GAA allele contained a null allele, and these
patients were used for clinical severity rating of GAA variants. The
reason for this is as follows. Usually, the second allele is a null allele,
from which no residual GAA enzyme activity is produced. Any
residual GAA enzyme activity is caused by the first allele. In this way,
the disease‐associated variant on the first allele can be rated. When
the second allele would also have residual GAA enzyme activity, both
alleles will contribute to the total residual GAA enzyme activity, and
it would not be possible anymore to attribute the activity and the
clinical severity rating to one of the two alleles. The remaining 140 of
562 GAA variants are classified as unknown (Table S4). The non‐
disease‐associated variants include alleles such as the Caucasian
variant c.271G>A (GAA2; MAF 0.02), and the Asian GAA variants
c.1726G>A (MAF 0.0179) plus c.2065G>A (MAF 0.08797;
Table S5). These variants have previously been shown to lower
(a)
(b)
F IGURE 1 The Pompe disease GAA variant database. (a) Flowchart for determining the clinical severity rating in the updated database.
(b) Screenshot of the updated Pompe disease GAA variant database home page at www.pompevariantdatabase.nl
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(a)
(b)
F IGURE 2 Frequencies of GAA variants and patients with specific GAA variants, stratified for disease severity. (a) Frequencies of unique
variants, classified at the RNA level (upper panel) and protein level (lower panel). The consequences of variants that affect pre‐mRNA splicing
was only included in specific categories (e.g., deletion, insertion, frameshift) at the protein level if experimental evidence was available. A list of
all included categories is shown in Table S6. (b) Frequencies of variant types in patients, classified at the RNA level (upper panel) and protein
level (lower panel). Two GAA alleles per patient were counted. Please note that 1) only one GAA allele could be counted in patients with an
unknown second GAA variant; and that 2) the allele was counted twice in patients with a homozygous genotype
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GAA enzymatic activity to some extent, however, they cannot cause
Pompe disease (M.A. Kroos et al., 2008; Shigeto et al., 2011; Swallow
et al., 1989; van Diggelen et al., 2009).
First, we performed stratification of GAA variants. At the RNA
level, substitutions were the predominant type of variants in all three
phenotype groups. Other types of variants including splicing variants
and deletions were present at a lower percentage without a clear
trend relative to the phenotype. At the protein level, analysis of
substitutions showed that the largest fraction was represented by
missense variants, followed by nonsense variants, again without a
clear trend relative to the phenotype. In 15% of cases, splicing
prediction of disease‐associated missense variants revealed possible
effects on splicing (Figure S1). The total number of unique variants
was similar between the three phenotype groups and ranged from
134 in adult to 154 in childhood and 173 in classic infantile patients.
A different result was obtained when the number of patients with
a certain type of variant was plotted per disease onset group. The
variants in all patients with a known phenotype were analyzed
(Figure S2). We note that two GAA variants per patients were
counted. A typical adult patient contains one null allele and one less
severe allele, whereas a classic infantile patient contains two null
alleles. In this case, the percentage of patients with a splicing variant
(intron variant) increased from less than 1% in the classic infantile
group to 18% in the childhood group and 44% in the adult group
(Figure 2b). At the protein level, this effect was reflected at the level
of the category deletion (translation initiation site), as the IVS1
variant causes skipping of the translation initiation site‐containing
exon 2. This effect can be attributed to the large number of childhood
and adult Caucasian Pompe patients with the splicing (intron variant)
variant c.‐32‐13T>G (IVS1). This variant leads to partial or complete
skipping of exon 2 during GAA pre‐mRNA splicing, which has been
described previously (Bergsma et al., 2015; Boerkoel et al., 1995;
Dardis et al., 2014; Huie, Chen, Brooks, Grix, & Hirschhorn, 1994; van
der Wal, Bergsma, Pijnenburg, van der Ploeg, & Pijnappel, 2017; van
der Wal, Bergsma, van Gestel et al., 2017).
3.3 | CRIM status of classic infantile variants
The CRIM status of a Pompe patient is determined by the combined
effect of both GAA variants: a CRIM negative patient has by
definition two CRIM negative variants. A CRIM positive patient has
either one CRIM positive (and one CRIM negative) or two CRIM
positive variants. Only for a limited number of variants, experimental
evidence of CRIM status, either by immunoblot or by RT‐PCR
analyses, has been published. This resulted in 46 CRIM negative, and
15 CRIM positive variants (Figure 3a,b). At the RNA level,
predominant categories for CRIM negative variants with experi-
mental evidence were substitutions, splicing (splice donor site),
deletions, and duplications (Figure 3a). At the protein level, most of
these variants were substitutions (nonsense) or frameshifts, both of
which cause premature translation initiation sites, whereas substitu-
tions (missense) were absent (Figure 3b). For CRIM positive variants
with experimental evidence, most variants were substitutions or
splicing variants. At the protein level, most variants were classified as
substitutions (missense) or deletions. A small fraction of CRIM
positive variants were frameshifts, suggesting that in these cases the
nonsense‐mediated decay pathway did not completely degrade the
mRNA.
Prediction of CRIM status was performed on the basis of the
variants’ effects on the reading frame, but it should be noted that
experimental validation is needed for these cases. 201 variants were
predicted to be CRIM positive, and these were substitutions
(missense) and deletions. Eighty‐five GAA variants were predicted
to be CRIM negative, the majority of which were frameshift and
substitution (nonsense) variants. The total numbers of classified
variants—that is those determined experimentally and those pre-
dicted—were 216 CRIM positive variants (62%) and 131 CRIM
negative variants (38%).
3.4 | Distribution of disease‐associated variants
along the GAA gene
Figure S3 shows that disease‐associated variants are distributed
throughout the GAA RNA (Figure S3A) and protein (Figure S3B) with
a slight enrichment in exons 4‐16 relative to the flanking exons. A
similar pattern was obtained when the distribution of variants was
plotted along exons according to clinical severity (Figure S3C). For
introns, disease‐associated variants were found in all introns except
for intron 5, without a clear pattern (Figure S3D). We note that
intronic variants are rarely investigated at the functional level and
that only the exon flanking regions are sequenced in standard
diagnostic analysis.
However, mapping of disease‐associated substitution (missense)
variants to functional GAA protein domains (Figure 4a), showed a
strong enrichment (up to seven‐fold) in the catalytic sites relative to
the N‐terminal signal peptide and the C‐terminal distal β‐sheet
(Figure 4b). Variants associated with the classic infantile phenotype
showed a similar enrichment in the catalytic sites. When GAA
variants in ExAC and dbSNP databases (which contains both disease‐
associated and non disease‐associated variants) were plotted, no
such enrichment in the catalytic domain was observed (Figure 4c).
These results are in line with the critical function of the catalytic core
for GAA enzyme activity.
3.5 | Geographic distribution of the most common
disease‐associated GAA variants
Table 1 shows the most common disease‐associated variants per
severity (when combined with a null allele), their geographical
distributions, and their linked phenotypes. We note that two CRIM
negative alleles are required to give rise to a CRIM negative
phenotype.
Variants associated with the classic infantile phenotype include
the very common variants c.525del (Caucasian, CRIM negative),
c.1935C>A (Asian, CRIM positive), and c.2481_102_2446+31del
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(delex18; Caucasian, CRIM positive). Other common variants
associated with the classic infantile phenotype include the CRIM
negative variants c.2560C>T (Latin American and African/African
American), c.1411_1414del (Asian), and c.2237G>A (Caucasian), and
the CRIM positive variants c.925G>A, c.1933G>A, c.784G>A, and
c.1655T>C (all mostly Caucasian).
Three common variants that are classified as either associated
with the classic infantile or childhood phenotypes include c.1064T>C
F IGURE 3 Distribution of CRIM
positive and CRIM negative variants per
variant type at the RNA level (a) and
protein level (b). Left panels in (a) and (b):
predicted variants; right panels:
experimentally tested variants. CRIM,
cross reactive immunologic material
(a)
(b)
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(Caucasian), c.670C>T (Caucasian and Asian), and c.1561G>A (Asian).
Variants associated with the childhood phenotype include the
common variants c.1857C>G, c.796C>T (both Asian), c.‐32‐3C>A
(Caucasian and Latin American), c.875A>G (Caucasian), and
c.1082C>T (Asian).
Variants that are associated with the childhood or adult
phenotypes are strongly dominated by the c.‐32‐13T>G (IVS1)
variant (Caucasian and Latin American). This variant is present in
86% (253/294) of patients in this category. Other common variants
associated with the childhood or adult phenotype include c.2238G>C
(Asian), c.2014C>T and 2173C>T (both Caucasian), and c.1634C>T
(Caucasian and Asian). Variants associated with the adult phenotype
include the common variants c.2647‐7G>A (Caucasian) and




F IGURE 4 Distribution of missense variants along the GAA protein. (a) Cartoon of the GAA gene indicating the locations of exons. Dark
brown regions indicate the 5′ and 3′ untranslated regions. The translation start codon is indicated as c.1 in exon 2. The second cartoon indicates
the GAA protein domains and the sites modified by M6P residues. (b) The distribution of disease‐associated variants in GAA protein domains
according to frequency and clinical severity rating. Numbers are corrected for the length of each domain. (c) as (b), but now for all GAA variants,
including both disease‐associated and non‐disease‐associated missense variants, listed in the ExAc database
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common disease‐associated variants can be found for each pheno-
type and geographical region.
4 | DISCUSSION
This study describes the extension of the Pompe mutation database
www.pompevariantdatabase.nl, which now includes a number of new
features to improve its utility. First, by linking variants to the patient
information reported in the literature, we have extended severity
ratings with the clinical phenotype. Second, we have added
information on the MAF, geographical distribution, onset and types
of clinical symptoms; and have performed predictions for a) effects
on splicing, b) severity of missense variants, and c) CRIM status.
Third, we have provided separate lists of null alleles, variants with an
'unknown' clinical severity rating, and variants that can lower the
activity of GAA without being capable of causing Pompe disease. An
important asset of the database—which is freely accessible online—is
that it provides comprehensive information on the genotype‐
phenotype relationship. In the previous version of the database, the
severity of the majority of GAA variants was predicted in silico. For a
subset of variants, expression studies were available. The extended
database now considers the clinical consequences of a GAA variant,
and it enables a better judgment of the potential severity of variants.
This is important for several aspects related to the diagnosis and
treatment of Pompe disease as outlined below.
4.1 | Novel aspects of the database
4.1.1 | Clinical information
Pompe disease has a broad spectrum of disease onset and symptoms. It
is important to be able to distinguish between classic infantile and late
onset phenotypes, because the classic infantile phenotype is so severe
that immediate treatment with ERT is required. This is reflected by
severe muscle weakness and hypertrophic cardiomyopathy, which
results in death within the first year of life if left untreated due tot
cardiorespiratory insufficiency. It has also become evident that classic
infantile patients slowly develop abnormalities in the central nervous
system as detected using nuclear magnetic resonance, which can result
in diminished intellectual performance (Ebbink et al., 2018). When
TABLE 1 Frequency and geographical distribution of most common GAA variants














c.525del 29 1 30
c.2560C>T 1 1 3 9 1 15
c.1411_1414del 11 11
c.2237G>A 5 1 6




c.2481+102_2646+31del 20 3 1 24
c.925G>A 7 1 8
c.1933G>A 4 2 1 7
c.784G>A 4 2 1 7
c.1655T>C* 5 1 6
Total 40 72 7 1 120
Classic infantile or
Childhood
c.1064T>C 9 3 2 14
c.670C>T 3 3 6
c.1561G>A 1 3 4
Total 13 9 2 24
Childhood c.1857C>G 6 6
c.796C>T 5 5
c.‐32‐3C>A 1 3 4
c.875A>G 3 1 4
c.1082C>T 1 3 4
Total 5 15 3 23
Childhood or Adult c.‐32‐13T>G 224 3 18 8 253
c.2238G>C 21 21
c.2014C>T 7 1 8
c.1634C>T 3 2 1 6
c.2173C>T 5 1 6
Total 239 27 1 19 8 294
Adult c.2647–7G>A 9 9
c.1585_1586delinsGT 4 4
Total 9 4 13
*The c.1655T>C variant has been classified to be associated with the classic infantile phenotype, although we note that three patients have been reported
that carry this variant and showed a childhood onset phenotype.
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patients have a late onset form of Pompe disease, at present it cannot
be accurately predicted when symptoms will arise and how severe these
will be. It is therefore important to collect the clinical information on
specific disease‐associated variants to better understand the genoty-
pe–phenotype relationships. These aspects are relevant for newborn
screening programs and genetic counseling.
4.1.2 | In silico predictions
Whereas clinical information is crucial for judging the severity of GAA
variants, in silico predictions can be helpful as they can provide part of
the evidence that leads to determination of the severity of variants. In
addition, in silico predictions can provide evidence for the underlying
mechanism involved in the disruption of GAA enzyme activity. For
example, splicing predictions can point to possible effects on splicing of
variants that would normally not be suspected of such effects. In
particular, missense variants are often not evaluated for their effect on
splicing, whereas several reports have suggested that missense variants
can often affect splicing (Lim, Ferraris, Filloux, Raphael, & Fairbrother,
2011; Soukarieh et al., 2016). Also in Pompe disease, we recently
described a missense variant (c.1075G>A; p.G359R) that appeared to
be disease‐associated mainly because it affects splicing rather than
changing the amino acids sequence. The effect of this variant was
predicted in silico, and this was experimentally confirmed (Bergsma
et al., 2015). On the other hand, predictions can also fail, such as is the
case for the IVS1 variant, which has an experimentally confirmed effect
on splicing that cannot be predicted in silico (Boerkoel et al., 1995;
Dardis et al., 2014; Huie et al., 1994; van der Wal, Bergsma, Pijnenburg
et al., 2017; van der Wal, Bergsma, van Gestel et al., 2017). In addition,
comparison of predictions of the severity of amino acid changes with
expression studies revealed failure of at least two out of three
prediction programs to predict the experimentally found deleterious
effect on GAA enzyme activity. This was the case for the following GAA
missense variants: c.307C>T, c.307C>G, c.380G>T, 701C>G, c.947A>T,
c.1040C>G, c.1381G>A, c.1456G>C, c.1834C>T, c.1905C>A,
c.2105G>T, and c.2210C>A. Conversely, there were also variants for
which in silico programs predicted a deleterious effect, while expression
studies showed no effect on enzyme activity. These variants included c.
664G>A, c.2132C>G. Finally, it is known that the strength of unnatural
transcription termination signals depends on the adjacent sequences
and that such signal can be ‘leaky’, reinforcing the need for experimental
confirmation (Dabrowski, Bukowy‐Bieryllo, & Zietkiewicz, 2015). In all
these cases, it is important to know whether a variant has some residual
enzyme activity, whether the GAA protein is still expressed, or whether
it is completely deleterious. This is crucial to make a distinction between
the classic infantile and late onset forms of Pompe disease, and within
the classic infantile population, to distinguish between CRIM positive
and CRIM negative patients.
4.1.3 | CRIM status
CRIM negative classic infantile patients generally have a poorer
prognosis compared to CRIM positive classic infantile patients when
treated with ERT. One of the explanations is the tendency of CRIM
negative patients to form high antibody titers during ERT (Kishnani
et al., 2010; van Gelder et al., 2016). This can be explained by the lack
of any endogenous GAA protein in CRIM negative patients, which
results in the recognition of rhGAA by the immune system and the
generation of rhGAA‐specific antibodies. However, most CRIM
positive patients with Pompe disease also develop anti‐rhGAA
antibodies, likely due to posttranslational differences between the
endogenous GAA protein and rhGAA, although on average the
antibody titers are lower in CRIM positive patients compared to
CRIM negative patients (Kishnani et al., 2010; Poelman et al., 2018).
Antibodies have the potential to interfere with ERT by binding to
rhGAA and thereby neutralizing its activity and/or uptake by muscle
cells. This has led to the exploration of immune modulating strategies
before the start of ERT in classic infantile patients (Elder et al., 2013;
Mendelsohn, Messinger, Rosenberg, & Kishnani, 2009; Messinger
et al., 2012), in particular in CRIM negative patients. At least 32% of
disease‐associated variants listed in the database have been shown
or predicted to be CRIM negative. Whereas the majority of missense
variants is predicted to be CRIM positive, missense variants that
affect splicing may be CRIM negative if they fully abrogate canonical
splicing and change the reading frame to introduce a premature stop
codon. For experimental validation of variants CRIM status, future
efforts should focus on performing standardized assays such as
immunoblot analysis combined with sensitive detection. As the
generation of leaky wild type splicing can be detected by RT‐PCR
analysis and is indicative of a CRIM positive status, such validation
should also include splicing analysis (Bergsma, van der Wal, Broeders,
van der Ploeg, & Pim Pijnappel, 2018), such as the splicing assay for
GAA that has been reported by us previously (Bergsma et al., 2015).
4.1.4 | MAF
The extended database now also includes information on the MAF
of variants. In general, a MAF of <1% is required for a variant to be
considered disease‐associated, because otherwise there would be
many more patients then found in reality. Relatively high MAFs
can be seen in the case of certain disease‐associated GAA variants
that are more frequent. The IVS1 variant, associated with late
onset Pompe disease, is truly disease‐associated but is clearly
enriched in the Caucasian population with a MAF of up to 0.8%.
Similarly c.1935C>A, a disease‐associated variant associated with
classic infantile Pompe disease is enriched in the Asian population
with a MAF of 0.17%. Novel variants for which the severity is
unknown should first pass the MAF <1% rule, and this is a useful
fast criterium to determine whether the variant could be
considered disease‐associated or not. This rule also applies to
variants that can lower GAA activity but not sufficiently to be truly
disease‐associated (meaning they can cause Pompe disease) on
their own. These include the GAA2 (c.271G>A) (MAF up to 4.9%)
variant in the Caucasian population and c.1726G>A; c.2065G>A
allele (MAF up to 14%) in the Asian population, both of which
are variants that lower GAA enzyme activity to some extent
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(M. A. Kroos et al., 2008). Considering their MAF and modest
effect on GAA activity, they cannot be considered disease‐
associated variants with sufficient deleterious effect to cause
Pompe disease. As screening and diagnostic procedures involve 4‐
MU as substrate, these variants can cause false‐positive results
that can be excluded using second tier DNA analysis.
4.1.5 | Geographical information
We have analyzed the geographical distribution of disease‐
associated variants and this indicated distinct sets of variants in
Caucasian and Asian populations. For instance, the IVS1 variant is
frequent in the Caucasian population but absent in people from
Asian descent, whereas the opposite is true for c.1935C>A. In
countries with mixed populations, it is difficult to attribute
variants to a certain descent. For example, in Latin America,
indigenous populations are mixed with Caucasians and people
from African and Asian descent. Many populations including those
from Africa, Russia, China, and more areas are currently not
covered by the database as it mostly includes variants found in
patients from Europe, North America, Australia, Taiwan, and
Japan. For future diagnostic purposes in other countries, it will be
important to extend the database beyond the current geographical
regions.
4.1.6 | Identification of disease‐associated variants
There are a number of patients in which only one GAA variant has
been identified. It is important to stress that this does not imply
that Pompe disease can be caused by only a single disease‐
associated variant. This is evident from the lack of symptoms in
carriers, such as the parents of Pompe patients. Most likely, lack of
identification of a second disease‐associated GAA variant is caused
by variants that are not detected by standard DNA diagnostics.
Currently, standard DNA diagnostic analysis involves Sanger
sequencing of exonic regions. This means that intronic regions,
5′ and 3′ untranslated regions, and the GAA promoter are not
examined, all of which could in principle harbor disease‐associated
variants. A first clue to the presence of such variant can be
provided by analysis at the mRNA level, which can reveal splicing
events or a lack of mRNA expression. We have shown that such
analysis is useful for detection of deep intronic variants and for
elucidating splicing events in fibroblasts (Bergsma et al., 2015), but
in principle such analysis may also be performed in blood. Small
deletions are analyzed using multiplex ligation‐dependent probe
amplification or DNA‐qPCR at diagnostic departments, but other
chromosomal aberrations such as deletions/duplications or uni-
parental disomy are currently not systematically analyzed. SNP
arrays have recently been shown to be useful for the detection of
such cases, which also occur in Pompe disease and may be useful
to include in standard DNA diagnostics (Labrijn‐Marks et al.,
2019).
4.1.7 | Utilization of the database for future
personalized medicine
Like ERT with rhGAA, next‐generation therapies are now under
development. Clinical trials have started for modified versions of
rhGAA, such as avaglucosidase alpha (former neoGAA; made by
Sanofi Genzyme); and ATB200/AT2221 (made by Amicus), which
combines rhGAA with a chaperone to improve the stability of ERT.
When used as single treatment without ERT, chaperones could be
used to treat a subpopulation of Pompe patients with certain
missense variants by preventing degradation of endogenous GAA
by the endoplasmatic reticulum‐associated protein degradation
pathway. The structure of rhGAA, which was solved recently
(Roig‐Zamboni et al., 2017), should aid the design of next
generation chaperones for personalized treatment, a process that
will be greatly supported by information in the Pompe mutation
database. When disease‐associated missense variants were
mapped on the GAA structure, we found enrichment of deleterious
variants in the catalytic domain, which is important for GAA
enzyme activity. The signal peptide/propeptide is involved in
protein targeting and activation (Choo, Tan, & Ranganathan,
2005), while the trefoil domain is found in a number of
extracellular proteins (http://pfam.xfam.org/family/PF00088) and
forms a secondary substrate binding site (Roig‐Zamboni et al.,
2017). Given their (potential) importance, it is surprising that a
relatively low percentage of disease‐associated missense variants
was found in the signal peptide/propeptide and trefoil domains.
Nevertheless, these domains also contained deleterious variants,
which may be relevant for the idea that chaperones could be
designed for trefoil domain variants that would have enhanced
specificity compared to catalytic domain chaperones, because the
catalytic domain is conserved in neutral glycosidases that would
mediate undesired side effects when targeted with a chaperone
(Roig‐Zamboni et al., 2017). If approved, other potential therapies
currently under preclinical development may, depending on the
predicted phenotype, be the most suitable for certain types of
Pompe patients. These include AAV‐mediated gene therapy
directed toward the diaphragm (Corti et al., 2017) or the liver
(Puzzo et al., 2017), hematopoietic stem cell‐mediated lentiviral
gene therapy (van Til et al., 2010), and splice switching antisense
oligonucleotides for the common c.‐32‐13T>G (IVS1) variant and
for other more rare childhood/adult variants (van der Wal,
Bergsma, Pijnenburg et al., 2017; van der Wal, Bergsma, van
Gestel et al., 2017). It will be important to continue updating and
improving the database as it forms an important reference point
for research on genotype‐phenotype relationships, diagnostics,
treatment regimen, and clinical trial design.
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